These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 14964044)

  • 1. Pfizer educational forum conference-Socratic dialogue: the body and mind: atypical antipsychotics, physical well-being and compliance. September 22nd, 2003 Prague, Czech Republic Municipal House, Square of Republic, 111 21 Prague 1 Czech Republic.
    Shelley P
    Int J Psychiatr Nurs Res; 2004 Jan; 9(2):1043-4. PubMed ID: 14964044
    [No Abstract]   [Full Text] [Related]  

  • 2. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The problem of drug compliance in schizophrenic patients].
    Albus M
    Psychiatr Prax; 1995 Nov; 22(6):221-2. PubMed ID: 8570750
    [No Abstract]   [Full Text] [Related]  

  • 4. Aripiprazole: novelty, adherence and understatement.
    Fear C
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):131. PubMed ID: 15469664
    [No Abstract]   [Full Text] [Related]  

  • 5. [Compliance in therapy of schizophrenic patients with neuroleptics--an overview].
    Mayer C; Soyka M
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):217-22. PubMed ID: 1353747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality of life and its association with insight, adverse effects of medication and use of atypical antipsychotics in patients with bipolar disorder and schizophrenia in remission.
    Yen CF; Cheng CP; Huang CF; Yen JY; Ko CH; Chen CS
    Bipolar Disord; 2008 Jul; 10(5):617-24. PubMed ID: 18657246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group.
    Br J Psychiatry Suppl; 1996 Dec; (31):21-30. PubMed ID: 8968652
    [No Abstract]   [Full Text] [Related]  

  • 9. [Compliance with treatment in schizophrenia and mood disorders].
    Sorvaniemi M; Kampman O
    Duodecim; 2000; 116(3):277-84. PubMed ID: 11764451
    [No Abstract]   [Full Text] [Related]  

  • 10. Schizophrenia and antipsychotic medication--better adherence, better outcomes?
    Staring AB; Van der Gaag M; Mulder CL
    Schizophr Res; 2013 Dec; 151(1-3):296-7. PubMed ID: 24238966
    [No Abstract]   [Full Text] [Related]  

  • 11. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects.
    Kao YC; Liu YP
    Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' subjective experiences of antipsychotics: clinical relevance.
    Hellewell JS
    CNS Drugs; 2002; 16(7):457-71. PubMed ID: 12056921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.
    Menzin J; Boulanger L; Friedman M; Mackell J; Lloyd JR
    Psychiatr Serv; 2003 May; 54(5):719-23. PubMed ID: 12719504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Depot antipsychotics in the year 2011].
    Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
    Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication adherence studies in schizophrenia.
    Hamann J; Pitschel-Walz G; Kissling W
    Am J Psychiatry; 2004 Mar; 161(3):582; author reply 582-3. PubMed ID: 14992997
    [No Abstract]   [Full Text] [Related]  

  • 19. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 20. [Combining effectiveness and tolerance].
    Krankenpfl J; 2005; 43(1-3):26-7. PubMed ID: 15912821
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.